NCT05057897 - A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

April 19, 2023

Study Completion Date

April 19, 2023

Conditions

COVID-19, SARS-CoV-2

Interventions

BIOLOGICAL

AZD1222

10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Trial Locations (4)

10700

Research Site, Bangkok

40002

Research Site, Khon Kaen

50200

Research Site, Muang

61052

Research Site, Kharkiv